As part of its Innovations in Vaccine Technologies program, Médicament Québec is investing $5.37 million to support four groundbreaking initiatives that will strengthen Quebec’s vaccine research and development capacity.
Vaccines are essential for preventing infections and represent a cornerstone of strategies aimed at preparing for future epidemics and pandemics. The development of new RNA vaccines against emerging pathogens relies on the rapid identification of antigenic targets capable of eliciting effective protection against infection. However, this crucial step is often limited by the lack of efficient screening tools. Moreover, there is a need for a preclinical platform to evaluate new formulations and the effectiveness of RNA vaccines.
RNA-based therapies and vaccines represent a versatile and preferred approach to addressing several major public health challenges. However, their production requires RNA to be encapsulated, stabilized, and delivered to the body using nanosuspensions complex structures that must be custom-formulated depending on the targeted organ or cells. This level of customization presents a significant challenge for large-scale production.
